Novel therapy for asthma

Expert Opinion on Investigational Drugs

Volumn 9, Issue 1, 2000, Pages 25-42

  Bryan, S A ^a   Leckie, M J ^a   Hansel, T T ^a   Barnes, P J ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Adhesion molecule antagonists; Allergy; Asthma; Bronchodilators; Chemokines; Corticosteroids; Cytokines; Eosinophils; IgE; IL 5; Inflammatory mediators; Interleukin; Leukotriene antagonists

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; AR 68397AA; BRONCHODILATING AGENT; CELL ADHESION MOLECULE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYTOKINE; FLUTICASONE PROPIONATE; GAMMA INTERFERON; HERBACEOUS AGENT; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 18; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; MONTELUKAST; PHOSPHODIESTERASE INHIBITOR; PRANLUKAST; PROTEIN KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 12; SALBUTAMOL; SALMETEROL; SALMETEROL PLUS FLUTICASONE; SB 255312; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ADRENAL SUPPRESSION; ASTHMA; BRONCHOSPASM; CATARACT; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENANTIOMER; EOSINOPHIL; FIRST AID; GENE THERAPY; GROWTH RETARDATION; HEADACHE; HUMAN; IMMUNOTHERAPY; NAUSEA; NONHUMAN; OSTEOPOROSIS; PALLIATIVE THERAPY; RECOMBINANT DNA TECHNOLOGY; REVIEW; VOMITING;

EID: 0033988244     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.1.25     Document Type: Review

References (143)